Valuation: Theraclion

Market Cap 49.06M 55.83M 45.47M 41.83M 79M 5.34B 80.67M 542M 212M 2.62B 210M 205M 9.07B P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 56.91M 64.77M 52.74M 48.52M 91.65M 6.2B 93.58M 629M 246M 3.04B 243M 238M 10.52B EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
54.37%
Yield 2024 *
-
Yield 2025 -
1 day-1.61%
1 week+8.05%
Current month+6.85%
1 month-10.29%
3 months+44.30%
6 months+10.00%
Current year+11.46%
1 week 0.64
Extreme 0.64
0.69
1 month 0.6
Extreme 0.605
0.8
Current year 0.4
Extreme 0.402
0.93
1 year 0.33
Extreme 0.33
1.25
3 years 0.14
Extreme 0.1416
1.25
5 years 0.14
Extreme 0.1416
2.22
10 years 0.14
Extreme 0.1416
7.72
Manager TitleAgeSince
Chief Executive Officer - 23/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 31/01/2018
Director/Board Member - 12/02/2019
Director/Board Member - 12/02/2019
Date Insider Type Main position Quantity % Market Cap.
06-07Sell

Director

-25,000 0.0342%
Change 5-day change 1-year change 3-year change Capi.($)
-1.61%+8.05%+89.55%+10.00% 57M
+0.28%+0.97%+21.54%+0.49% 196B
+0.08%-4.43%-20.49%+17.13% 144B
+0.56%+1.13%-2.29%-15.94% 141B
-0.27%-1.09%-56.73%-14.89% 66.54B
-0.46%-2.73%+17.60%-1.41% 53.09B
+2.80%+1.69%-22.83%-29.39% 44.12B
-0.19%+2.56%+8.73%+11.70% 37.93B
-0.85%-1.60%+5.76%+38.77% 36.96B
+0.94%-0.39%-13.07%-20.05% 29.43B
Average +0.13%+0.30%+2.78%-0.36% 74.89B
Weighted average by Cap. +0.29%-0.83%-3.66%-1.01%

Financials

2024 2025
Net sales 830K 945K 769K 708K 1.34M 90.4M 1.37M 9.18M 3.59M 44.42M 3.55M 3.47M 154M 652K 742K 604K 556K 1.05M 70.99M 1.07M 7.21M 2.82M 34.89M 2.79M 2.72M 121M
Net income -5.76M -6.55M -5.34M -4.91M -9.27M -627M -9.47M -63.65M -24.91M -308M -24.6M -24.06M -1.06B -5.69M -6.48M -5.27M -4.85M -9.16M -620M -9.36M -62.91M -24.62M -304M -24.32M -23.78M -1.05B
Net Debt 3.41M 3.88M 3.16M 2.91M 5.49M 371M 5.61M 37.71M 14.76M 182M 14.58M 14.25M 631M 7.85M 8.94M 7.28M 6.69M 12.65M 855M 12.91M 86.81M 33.97M 420M 33.55M 32.81M 1.45B
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36
Date Price Change Volume
13/07/26 €0.6710 -1.61% 18,094
10/07/26 €0.6820 +1.79% 31,729
09/07/26 €0.6700 +1.67% 17,476
08/07/26 €0.6590 -1.64% 41,279
07/07/26 €0.6700 -2.33% 66,216

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALTHE Stock